Cann Group

Cann Group Financial Debt Ratio

The Financial Debt Ratio of Cann Group (CAN.AX) as of Oct 20, 2026 is 32.39 %. In the previous year, Financial Debt Ratio was 96.26 % — a change of -66.35% (lower).

Financial Debt Ratio

32.39 %

YoY

-66.35%

Last updated:

Financial Debt Ratio of Cann Group is 2026 32.39 % . Financial Debt Ratio of Cann Group was 2025 96.26 % . It decreases by -66.35% lower compared to the previous year.

The Cann Group Financial Debt Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Debt Ratio
Date
Financial Debt Ratio
Jan 1, 2019
11.35 AUD
Jan 1, 2020
12.20 AUD
Jan 1, 2021
0.67 AUD
Jan 1, 2022
33.77 AUD
Jan 1, 2023
47.09 AUD
Jan 1, 2024
78.11 AUD
Jan 1, 2025
96.26 AUD
Jan 1, 2026
32.39 AUD
The Cann Group Financial Debt Ratio history
YEARFinancial Debt RatioYoY
32.39 %-66.35%
96.26 %+23.23%
78.11 %+65.88%
47.09 %+39.44%
33.77 %+4,955.26%
0.67 %-94.52%
12.20 %+7.48%
11.35 %+47,810.11%
0.02 %-85.58%
0.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cann Group Stock analysis

What does Cann Group do? Cann Group Ltd is an Australian company specializing in the production and marketing of medical cannabis. The company was founded in 2013 and is headquartered in Melbourne. The company's history began with the founding of an independent consulting firm called AusCann Group Holdings Ltd in 2014. This firm was created to inform Australian and international investors about the opportunities and possibilities in the Australian cannabis market. In 2016, a cooperation agreement was signed between AusCann and Cann Group Ltd to advance the cultivation and production of medical cannabis products in Australia. Since then, Cann Group has continuously invested in the development and growth of the Australian medical cannabis market. The company has obtained a Good Manufacturing Practices (GMP) compliance license to ensure that all products meet the highest quality and safety standards. This includes collaborating with research institutions and state health authorities to investigate the efficacy and safety of medications. Cann Group's various business areas include the production of medical cannabis, research, product development, and marketing. The company operates a cannabis cultivation facility in Cochranes Hill, Victoria, covering an area of 20 hectares. The cultivation of cannabis is carried out under controlled conditions to ensure that all products are of the highest quality and purity. The cultivated cannabis is then used to manufacture medical products such as oils, tinctures, capsules, and sprays. Cann Group also collaborates closely with research institutions and academic institutions to study the safety and efficacy of medical cannabis. The company has partnerships with the University of Melbourne, Queensland University of Technology, and Swinburne University of Technology for research on the mechanisms of cannabis, application research, and studies on the clinical efficacy of cannabis. The business model of Cann Group is based on the sale of medical cannabis products to pharmacies and medical facilities in Australia and worldwide. The company, through its license, is one of the few companies capable of producing and exporting medical cannabis for the Australian market. In addition to exporting cannabis products to Germany, New Zealand, the UK, and other countries, the sale of cannabis products to the Australian market is the largest market for Cann Group. The company offers a variety of medical cannabis products specifically developed for various medical conditions. These include products for anxiety, nausea and vomiting, pain, seizures, and many other diseases. There are also products for palliative care, which help alleviate pain and suffering in the final stages. Overall, Cann Group Ltd has played a pioneering role in the development of the Australian medical cannabis market in recent years. The company specializes in the production of medical cannabis products that meet the highest quality standards and strict regulatory requirements. The company is committed to improving the therapeutic approach to diseases and enhancing the quality of life for patients. Cann Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cann Group stock

Financial Debt Ratio of Cann Group is 32.39 % in 2026.

Financial Debt Ratio of Cann Group changed from 96.26 % to 32.39 %, representing a -66.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Debt Ratio Cann Group since 2006 – with annual values, charts, and detailed analysis.

The financial debt ratio measures interest-bearing financial debt as a percentage of total assets. It isolates funded debt from trade and other non-financial obligations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Debt Ratio's Cann Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Cann Group

All Key Metrics — Cann Group